Securities code: 300639 securities abbreviation: Guangdong Hybribio Biotech Co.Ltd(300639) Announcement No.: 2022-005 Guangdong Hybribio Biotech Co.Ltd(300639)
Announcement on wholly owned subsidiary obtaining Australian patent certificate
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Recently, Guangzhou Kaipu Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Kaipu pharmaceutical”) and Guangzhou Guangdong Hybribio Biotech Co.Ltd(300639) Technology Co., Ltd. (hereinafter referred to as “Guangzhou Kaipu”) which are wholly-owned subsidiaries of Guangdong Hybribio Biotech Co.Ltd(300639) (hereinafter referred to as “the company”) have obtained patent certificates issued by the Australian Intellectual Property Office (IP Australia). The details are as follows:
Invention name patent No. patent application date patent right term
Chloroquine gel and preparation method and
November 2019: Twenty from the date of application, 2019391079
Chloroquine gel and its preparation method and for 4 days
(used)
The company has developed the drug “chloroquine phosphate gel” by using the technology of the invention. At present, clinical trials on effectiveness and safety evaluation of II are being carried out, and the test is progressing smoothly. The indication of “phosphate chloroquine gel” is the external use of skin for the treatment of various skin warts, external genitalia and perianal condyloma caused by HPV virus infection. It is a new indication not yet approved by China. External administration through skin can reduce systemic drug exposure and improve the effectiveness and safety of drugs.
The above patents have been authorized by China, the United States, Russia, Australia, South Korea and Japan. The acquisition of foreign inventions will help the company give full play to the advantages of independent intellectual property rights, strengthen the international protection of independent intellectual property rights, further improve the company’s intellectual property system, promote the continuous enrichment of the company’s product structure and enhance the company’s core competitiveness, It will not have a significant impact on the current operation of the company.
It is hereby announced.
Guangdong Hybribio Biotech Co.Ltd(300639) board of directors January 19, 2002
